HealthDay News — The Pfizer/BioNTech COVID-19 vaccine is more than 91 percent effective six months after people get their second dose, according to new test data released by the companies.
The findings from more than 46,000 trial participants was released Thursday, CBS News reported. There were 927 confirmed symptomatic cases of COVID-19 overall, with 850 cases in the placebo group and 77 cases among those who received the vaccine.
The companies also announced that the vaccine is safe and effective in children as young as 12 years, and they plan to seek emergency use authorization in the United States and Europe for the vaccine to be given starting at age 12 years, CBS News reported.
That means that children 12 years and older could start receiving the vaccine before going back to school in the fall.